The article focuses on the EMPULSE trial, which evaluated the impact of empagliflozin on decongestion in acute heart failure (AHF). Topics include the trial's design and methodology, the comparison of empagliflozin to a placebo, and the trial's findings related to weight ...
(上下滑动可查看) [1]Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial[J]. Nat Med, 2022, 28(3): 568-574. [2]Velazquez ...
ACC.22丨EMPULSE 急性心力衰竭(AHF)住院患者的健康状况较差,包括较高的疾病负担和身体活动限制,生活质量较差。到目前为止,在AHF患者中,还缺乏对这些结果有令人信服的治疗方法。钠葡萄糖共转运蛋白2(SGLT2)抑制剂是目前心衰患者的一种治疗...
[1]Primary publication - TBC [2]Voors AA, Angermann CE, Teerlink JR,et al., for the EMPULSE Trial Investigators. Empagliflozin in patients hospitalized for acute heart failure: the EMPULSE trial. Presented at the 2021 American Heart Association Scientific Sessions, Virtual;November 14, 2021. Lat...
Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021 Aug 27....
from the body and reducing the fluid load of the body’s blood vessel system (i.e. intravascular volume). Empagliflozin induces changes to the sugar, salt and water metabolism in the body that may contribute to the reductions in cardiovascular death observed in the EMPA-REG OUTCOME® trial....
Methods and results The primary trial outcome is a hierarchical composite of death, number of HF events, time to first HF event, or a ≥5‐point difference in Kansas City Cardiomyopathy Questionnaire (KCCQ) total symptom score change at 90?days. In an overall (unstratified) analysis we show ...
Efficacy and Safety of Empagliflozin in Hospitalized Heart Failure Patients: Main Results from The Empulse Trialdoi:10.1016/j.hrtlng.2022.06.007Adriaan Voors MDChristiane Angermann MDJohn Teerlink MDSean Collins MD, MScMikhail Kosiborod MDJan Biegus MD...
In this issue of the Journal, Tromp et al. conducted a post-hoc analysis of the EMPULSE trial and explored the efficacy, safety, and tolerability of empagliflozin across the full range of LVEF.doi:10.1002/ejhf.3256Lien, TannSrikanth, KishanAmbrosy, Andrew P.European Journal of Heart Failure...